AAMU
CYCN icon

Amundi Asset Management US’s Cyclerion Therapeutics CYCN Stock Holding History

Amundi Asset Management US’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed – – 1544
2020
Q4 		$0 Hold
2
– – ﹤0.01% 1497
2020
Q3 		$0 Hold
2
– – ﹤0.01% 1611
2020
Q2 		$0 Hold
2
– – ﹤0.01% 1631
2020
Q1 		$0 Hold
2
– – ﹤0.01% 1611
2019
Q4 		$0 Hold
2
– – ﹤0.01% 1618
2019
Q3 		$0 Sell
2
-25
-93% -$5.4K ﹤0.01% 1645
2019
Q2 		$6K Buy
+27
New +$7.64K ﹤0.01% 1627

Other funds holding CYCN

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Amundi Asset Management US's CYCN Position: Q1 2021 in Review

Amundi Asset Management US sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 2 shares.

Amundi Asset Management US first reported a position in CYCN in Q2 2019 and held it in 7 quarters. The position peaked at $6K in Q2 2019. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

  • Amundi Asset Management US reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Amundi Asset Management US sold 2 Cyclerion Therapeutics shares in Q1 2021.
  • Amundi Asset Management US first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 7 quarters.
  • Amundi Asset Management US's Cyclerion Therapeutics position peaked at $6K in Q2 2019.
  • 70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.